Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer

다국어 초록 (Multilingual Abstract)

Purpose: Great progress has been made in the adjuvant treatment of colon cancer. The aim of this study was to evaluate the efficacy of postoperative adjuvant chemotherapy using the FOLFOX regimen in patients with stage III and high-risk stage II colon cancer.
Methods: Eighty-two patients who underwent a potentially curative resection for stage III or high-risk stage II colon cancer were enrolled in this retrospective study. They received FOLFOX4 or modified FOLFOX6. The primary endpoint was disease-free survival.
Results: During the median follow-up of 37 months (range, 21 to 61 months), 14 patients experienced disease relapse. The disease-free survival rate at 3 years was 82.9%: 84.6% for stage II and 82.6% for stage III. At the time of the analysis, 8 patients were dead from recurrence. The probability of overall survival at 5 years was 74.5%: 90% for stage II and 74.6% for stage III. Grade 3 or 4 hematologic adverse events included neutropenia (40.2%), anemia (2.4%), and thrombocytopenia (1.2%). Gastrointestinal toxicities included grade 3 or 4 nausea (4.9%) and stomatitis (2.4%). Peripheral sensory neuropathy was observed in 81.7% of the patients during treatment. Of the 11 patients (13.4%) who had grade 3 peripheral sensory neuropathy during treatment, grade 3 symptoms were persistent in 3 patients with gait disturbance at the time of analysis.
No treatment-related deaths were recorded.
Conclusion: Postoperative chemotherapy using the FOLFOX regimen, oxaliplatin in combination with 5-fluorouracil and leucovorin, is effective and tolerable in patients with stage III and high-risk stage II colon cancer.

참고문헌 (Reference)

1 Sargent D, "Two or three year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803" 47 : 990-996, 2011

2 Andre T, "Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial" 21 : 2896-2903, 2003

3 Sadahiro S, "Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years" 50 : 1362-1366, 2003

4 Andre T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer" 350 : 2343-2351, 2004

5 Kuebler JP, "Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07" 25 : 2198-2204, 2007

6 Moertel CG, "Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma" 322 : 352-358, 1990

7 de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer" 18 : 2938-2947, 2000

8 Obrand DI, "Incidence and patterns of recurrence following curative resection for colorectal carcinoma" 40 : 15-24, 1997

9 Andre T, "Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial" 27 : 3109-3116, 2009

10 Sargent DJ, "Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials" 23 : 8664-8670, 2005

11 Wolmark N, "Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04" 17 : 3553-3559, 1999

12 Teichgraber UK, "Central venous port systems as an integral part of chemotherapy" 108 : 147-153, 2011

13 Biffi R, "Catheter rupture and distal embolisation: a rare complication of central venous ports" 1 : 19-22, 2000

14 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008" 대한암학회 43 (43): 1-11, 2011

15 Goldberg RM, "A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer" 22 : 23-30, 2004